Clinical trial
Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel…
NCT00436709 · Memorial Sloan Kettering Cancer Center, Other · Unknown status
Key facts
| NCT number | NCT00436709 |
|---|---|
| Title | Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer |
| Official title | A Pilot Study of Bevacizumab With Dose Dense Doxorubicin and Cyclophosphamide (AC) Followed by Dose Dense Nanoparticle Albumin Bound Paclitaxel for the Treatment of Early Stage Breast Cancer |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug, Other, Procedure |
| Interventions | bevacizumab, pegfilgrastim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation, flow cytometry, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, adjuvant therapy and 1 more |
| Enrollment | 75 |
| Start date | Jul 1, 2006 |
| First posted | Feb 19, 2007 |
| Last update posted | Jan 6, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: